PARP Imaging with [18F]Florathanatrace for Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores a new method to detect cancer activity using PET scans with a special tracer called [18F]FluorThanatrace (a radiotracer). The aim is to determine if this tracer can help doctors better understand cancer by highlighting activity related to the protein PARP-1. The trial has two parts: one examines how the tracer moves in the body, involving both cancer patients and healthy volunteers, while the other assesses how the tracer behaves in tumors, involving only cancer patients. Individuals with head and neck, lung, or other cancers treated with platinum-based chemotherapy might be suitable candidates, especially if they have a tumor at least 1 cm in size. As an Early Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this innovative tracer.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that [18F]FluorThanatrace is safe for PET imaging in cancer patients?
Research has shown that [18F]FluorThanatrace, a new imaging tracer, has been tested in early studies with patients who have breast and ovarian cancer. These studies used the tracer to visualize an enzyme linked to cancer growth. Although detailed safety information from these studies is limited, the tracer's progression to human testing suggests it was generally well-tolerated in earlier tests.
As this study is in an early phase, researchers are closely monitoring the tracer's safety in humans. Specific side effects from earlier studies have not been detailed. However, advancing to human trials usually indicates some initial confidence in its safety from prior tests. So far, no major safety concerns have emerged with [18F]FluorThanatrace, but ongoing trials will provide more information.12345Why are researchers excited about this trial?
Researchers are excited about [18F]FluorThanatrace because it offers a new way to visualize cancer activity using PET/CT imaging. Unlike current treatments that often rely on invasive biopsies to understand tumor dynamics, [18F]FluorThanatrace is a radiotracer that highlights PARP enzyme activity directly in the body. This method allows for real-time insights into tumor behavior and metabolism, potentially leading to more precise and personalized treatment strategies. By providing a clearer picture of how cancer cells are functioning, this approach could revolutionize how doctors monitor and adapt cancer treatment plans.
What evidence suggests that this imaging technique is effective for cancer?
Research has shown that \[18F\]FluorThanatrace (\[18F\]FTT) effectively images cancer by targeting a protein called PARP-1, which aids in DNA repair. Studies have found that \[18F\]FTT can highlight PARP-1 activity in breast and ovarian cancer and detect PARP-1 in prostate cancer, making it a promising tool for visualizing various tumors. In this trial, participants in the Dosimetry Studies Arm will undergo whole-body PET/CT imaging to determine the whole-body dosimetry of \[18F\]FTT. Meanwhile, participants in the Kinetic Studies Arm will undergo a 1-hour dynamic scan to determine the tracer's kinetics in tumors. This imaging method helps doctors assess cancer cell activity, potentially guiding treatment decisions. Overall, \[18F\]FTT holds promise for enhancing the understanding and management of cancer through PET imaging.35678
Who Is on the Research Team?
Farrokh Dehdashti, M.D.
Principal Investigator
Washington University School of Medicine
Are You a Good Fit for This Trial?
This trial is for adults with a tumor at least 1 cm in size, or healthy volunteers without cardiopulmonary issues (for different study arms). It's open to those with certain cancers treatable by platinum-based chemo. People can't join if they can't follow the study plan, stay still in a PET/CT scanner, have incompatible implants, non-measurable disease under 1 cm, or conditions like claustrophobia that prevent imaging sessions.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dosimetry Studies
Participants undergo whole-body PET/CT imaging to determine the whole body dosimetry of [18F]FluorThanatrace
Kinetic Studies
Participants undergo a 1-hour dynamic scan upon injection of [18F]FluorThanatrace to determine the kinetics of the tracer in tumors
Follow-up
Participants are monitored for safety and effectiveness after imaging studies
What Are the Treatments Tested in This Trial?
Interventions
- [18F]FluorThanatrace
Find a Clinic Near You
Who Is Running the Clinical Trial?
Washington University School of Medicine
Lead Sponsor